Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates

Urogen Pharma (URGN) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.68 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 34.52%. A quarter ago, it was expected that this company would post a loss of $0.82 per share when it actually produced a loss of $0.91, delivering a surprise of -10.98%.Over the last four quarters, the company has surpassed ...